Table 1 Baseline Characteristics
No. (%) | |
|---|---|
Total N | 152 (100) |
Median age (range), years | 61 (21–82) |
Sex | |
Male | 72 (47%) |
Female | 80 (53%) |
Performance status | |
ECOG 0–1 | 149 (98%) |
ECOG ≥2 | 3 (2%) |
Subtypes | |
Acral | 58 (38%) |
Mucosal | 47 (31%) |
Cutaneous | 36 (24%) |
Uveal | 4 (2%) |
Other (unclassifiable) | 7 (5%) |
M staging of extent of metastasis | |
M0 | 23 (15%) |
M1a | 38 (25%) |
M1b | 38 (25%) |
M1c | 42 (28%) |
M1d | 11 (7%) |
BRAFV600 status (n = 133) | |
Mutant | 23/133 (17%) |
Wildtype | 110/133 (83%) |
KIT status (n = 98) | |
Mutant | 14/98 (14%) |
Wildtype | 84/98 (86%) |
Lactate dehydrogenase concentration | |
Normal | 101 (66%) |
Elevated | 32 (21%) |
Unknown | 19 (13%) |
Number of lines of previous systemic therapies | |
0 | 96 (63%) |
1 | 28 (18%) |
2 | 22 (15%) |
≥3 | 6 (4%) |
Type of previous treatment | |
Ipilimumab | 17 (11%) |
Interleukin-2 | 2 (1%) |
BRAF/MEK inhibitor | 6 (4%) |
Cytotoxic chemotherapy | 45 (30%) |